Bacterial detection of platelets: Current problems and possible resolutions

被引:115
作者
Blajchman, MA
Beckers, EAM
Dickmeiss, E
Lin, L
Moore, G
Muylle, L
机构
[1] McMaster Univ, Dept Pathol, Hamilton, ON L8N 3Z5, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada
[3] Canadian Blood Serv, Hamilton, ON, Canada
[4] Sanquin Blood Bank SW Reg, Rotterdam, Netherlands
[5] Rigshosp, Copenhagen Blood Transfus Serv Ctr, DK-2100 Copenhagen, Denmark
[6] Cerus Corp, Concord, CA USA
[7] Queen Elizabeth Hosp, Kings Lynn, England
[8] Red Cross Flanders Blood Serv, Mechelen, Belgium
[9] Univ Antwerp, B-2020 Antwerp, Belgium
关键词
D O I
10.1016/j.tmrv.2005.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The greatest transfusion-transmitted disease risk facing a transfusion recipient is that of bacterial sepsis. The prevalence of bacterial contamination in platelets and red blood cells is approximately 1 in 3000 units transfused. The available data indicate that transfusion-associated sepsis develops after 1 in 25000 platelet transfusions and 1 in 250000 red blood cell transfusions. One of the most widely used strategies for decreasing bacterial sepsis risk is bacterial detection. A roundtable meeting of experts was convened during the XXVIII Annual Congress of the International Society of Blood Transfusion (Edinburgh, UK, July 2004) to provide a forum for experts to share their experiences in the routine bacterial detection of platelet products. This article summarizes the presentations, discussions, and recommendations of the panel. The data presented indicate that some of the current bacterial screening technology is useful for blocking the issuance of platelet units that contain relatively high levels of contaminating bacteria. Platelet units are usually released based on a test-negative status, which often become test-positive only upon longer storage. These data thus suggest that bacterial screening may not prevent all transfusion-transmitted bacterial infections. Two transfusion-transmitted case reports further highlighted the limitation of the routine bacterial screening of platelet products. It was felt that newer technologies, such as pathogen inactivation, may represent a more reliable process, with a higher level of safety. The panel thus recommended that the Transfusion Medicine community may need to change its thinking (paradigm) about bacterial detection, toward the possibility of the pathogen inactivation of blood products, to deal with the bacterial contamination issue. It was suggested, where permitted by regulatory agencies, that blood centers should consider adopting first-generation pathogen inactivation systems as a more effective approach to reducing the risk of transfusion-associated sepsis than some of the approaches currently available. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:259 / 272
页数:14
相关论文
共 27 条
[11]  
CLAEYS H, 2003, TRANSFUS MED S1, V1, P326
[12]   Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections [J].
de Korte, D ;
Marcelis, JH ;
Verhoeven, AJ ;
Soeterboek, AM .
VOX SANGUINIS, 2002, 83 (01) :13-16
[13]   Proceedings of a consensus conference: Towards an understanding of TRALI [J].
Goldman, M ;
Webert, KE ;
Arnold, DM ;
Freedman, J ;
Hannon, J ;
Blajchman, MA .
TRANSFUSION MEDICINE REVIEWS, 2005, 19 (01) :2-31
[14]  
Hillyer Christopher D, 2003, Hematology Am Soc Hematol Educ Program, P575
[15]   Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function [J].
Knutson, F ;
Alfonso, R ;
Dupuis, K ;
Mayaudon, V ;
Lin, L ;
Corash, L ;
Högman, CF .
VOX SANGUINIS, 2000, 78 (04) :209-216
[16]   Transfusion-transmitted bacterial infection in the United States, 1998 through 2000 [J].
Kuehnert, MJ ;
Roth, VR ;
Haley, NR ;
Gregory, KR ;
Elder, KV ;
Schreiber, GB ;
Arduino, MJ ;
Holt, SC ;
Carson, LA ;
Banerjee, SN ;
Jarvis, WR .
TRANSFUSION, 2001, 41 (12) :1493-1499
[17]   Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria [J].
Lin, L ;
Dikeman, R ;
Molini, B ;
Lukehart, SA ;
Lane, R ;
Dupuis, K ;
Metzel, P ;
Corash, L .
TRANSFUSION, 2004, 44 (10) :1496-1504
[18]   Inactivation of cytomegalovirus in platelet concentrates using Helinx™ technology [J].
Lin, L .
SEMINARS IN HEMATOLOGY, 2001, 38 (04) :27-33
[19]  
LIN L, 2005, IN PRESS TRANSFUSION
[20]   Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial [J].
McCullough, J ;
Vesole, DH ;
Benjamin, RJ ;
Slichter, SJ ;
Pineda, A ;
Snyder, E ;
Stadtmauer, EA ;
Lopez-Plaza, I ;
Coutre, S ;
Strauss, RG ;
Goodnough, LT ;
Fridey, JL ;
Raife, T ;
Cable, R ;
Murphy, S ;
Howard, F ;
Davis, K ;
Lin, JS ;
Metzel, P ;
Corash, L ;
Koutsoukos, A ;
Lin, L ;
Buchholz, DH ;
Conlan, MG .
BLOOD, 2004, 104 (05) :1534-1541